Cytokinetics Inc (CYTK)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Cardiovascularsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-16. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 50/100 (MEDIUM), 5.8 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 15.61% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Aficamten’s ACACIA-HCM Multi-Domain Gains Might Change The Case For Investing In Cytokinetics (CYTK)
- Cytokinetics (CYTK), What Is Behind The Fresh Attention?
- Cytokinetics (CYTK) Stock Looks Hard To Pin Down Following Strong Heart Drug Updates
- Cytokinetics (CYTK) Reports Phase 3 Aficamten Gains In Non Obstructive HCM
- Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
- Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
- Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
- Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Cytokinetics Inc.
Full CYTK Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.